Table 1.

Ongoing phase 3 clinical trials using monoclonal antibodies against proprotein convertase subtilisin/kexin 9

Monoclonal antibody used	Evolocumab by Amgen	Alirocumab by Sanofi/Regeneron	Bococizumab by Pfizer
Phase 3 trial	FOURIER	ODYSSEY outcome	SPIRE I/II
Enrollment (n)	22 500	18 000	17 000/9000
Inclusion criteria	Age 40–85, History of CVD with high risk of recurrent event, LDL-c >70 mg/dl, triglycerides <400 mg/dl	Age >40, hospitalized of Acute Coronary Syndrome in the last 52 weeks before enrollment, LDL-c >70 mg/dl	I – Age >18, background of lipid-lowering treatment, at high risk of a cardiovascular event, LDL 70–100 mg/dl II – Age >18, background of lipid lowering treatment, at high risk of a cardiovascular event, LDL >100 mg/dl
Subcutaneous injection intervals	Once every 2 weeks		Once every 2 weeks
End date	02.2018	03.2018	06.2018/03.2018

FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; LDL, low-density lipoprotein; ODYSSEY; SPIRE, The Evaluation Of PF-04950615 (RN316), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.